CN101780270A - Compound soluble powder for treating respiratory diseases of birds - Google Patents
Compound soluble powder for treating respiratory diseases of birds Download PDFInfo
- Publication number
- CN101780270A CN101780270A CN201010131385A CN201010131385A CN101780270A CN 101780270 A CN101780270 A CN 101780270A CN 201010131385 A CN201010131385 A CN 201010131385A CN 201010131385 A CN201010131385 A CN 201010131385A CN 101780270 A CN101780270 A CN 101780270A
- Authority
- CN
- China
- Prior art keywords
- birds
- soluble powder
- compound soluble
- treatment
- growth factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to compound soluble powder for treating respiratory diseases of birds. The compound soluble powder is prepared by mixing the following components by taking 100g as unit weight: 5-20g of tylosin tartrate, 10-30g of doxycycline hydrochloride, 5-10g of ribavirin, 5-20g of N- acetylcysteine, 2-5g of epidermal growth factor, and the balance of pharmaceutically applicable auxiliary material. The pharmaceutically applicable auxiliary material is anhydrous dextrose or oral glucose, and is preferably the anhydrous dextrose. The invention adopts a compound preparation combining antibiotic medicaments, antivirus medicaments, expectorants and the epidermal growth factor and can effectively and fast treat the respiratory diseases of birds. The invention has the advantages of simple preparation, remarkable effect and wide application.
Description
Technical field
The present invention relates to a stud bird medication thing, particularly a kind of compound soluble powder that is used for the treatment of respiratory disease of birds.
Background technology
Fowl upper disease all is a difficult problem that is perplexing the birds raiser all the time, its sickness rate is high and cause the secondary infection of multiple disease easily, have a strong impact on weightening finish and the efficiency of feed utilization of birds, make the chick growth hypoevolutism, the chicken egg drop reduction of growing up and the chicken death that causes various ages in days, medical expense makes that more feeding cost is multiplied, and causes very big economic loss to the raiser.
Current, the respiratory tract disease that has a strong impact on birds production mainly contains atypia newcastle disease, bird flu, infectious laryngotracheitis, colibacillosis and mycoplasma etc.These diseases often are not single generations when taking place, but occur with multiple cause of disease mixed infection form.Clinical manifestation for shed tears, rhinorrhea, cough or sneeze, breathe, respiratory symptom such as dyspnea.
Therefore, a kind of broad-spectrum antiseptic, antiviral being provided, human body nonhazardous, environmentally safe, fowl that security performance is high are used respiratory drugs, will be one of current urgent problem of these those skilled in the art.
Summary of the invention
The object of the invention is to overcome the deficiencies in the prior art part, provides a kind of technology simple and enlarge antibiotic, the antiviral scope of medicine, and the compound soluble powder that is used for the treatment of respiratory disease of birds that is difficult for developing immunity to drugs, and effectively controls secondary infection.
The technical solution adopted in the present invention is for achieving the above object:
A kind of compound soluble powder that is used for the treatment of respiratory disease of birds, it is characterized in that: by 100g is that Unit Weight is mixed and made into by following component: tylosin tartrate 5-20g, doxycycline hydrochloride 10-30g, ribavirin 5-10g, N-acetylcystein 5-20g, epidermal growth factor 2-5g, surplus is the adjuvant that pharmaceutically is suitable for.
By 100g is that Unit Weight is mixed and made into by following preferable content component: tylosin tartrate 20g, doxycycline hydrochloride 20g, ribavirin 5g, N-acetylcystein 10g, epidermal growth factor 5g, surplus is the adjuvant that pharmaceutically is suitable for.
The described adjuvant that pharmaceutically is suitable for is anhydrous glucose or oral glucose, is preferably anhydrous glucose.
The characteristic of the various medicines of the present invention and composition principle:
Tylosin tartrate: tylosin be a kind of efficient, low toxicity the animal specific macrolide antibiotics, can combine with procaryotic ribosome in vivo, it is synthetic that hindered aminoacid participates in peptide chain, thereby suppress the synthetic of infection protein matter.Gram positive bacteria, some gram negative bacteria, spirillum also there is inhibitory action.Sensitive organism has staphylococcus aureus, streptococcus pyogenes, streptococcus pneumoniae, corynebacterium pyogenes etc.Effective especially to Mycoplasma, be one of the strongest medicine of macrolide apoplexy due to endogenous wind anti-mycoplasma effect.
Doxycycline hydrochloride: the another name doxycycline belongs to tetracycline antibiotics.This product is a broad-spectrum antibacterial agent, tool bactericidal action during high concentration.Many rickettsiaes, Mycoplasma, chlamydiaceae, anonymous mycobacteria genus, spirillum are also to this product sensitivity.Effect is better than gram negative bacteria to this product to gram positive bacteria, but Enterococcus is to its drug resistance.This product mechanism of action is that medicine can combine with the A position of bacterial ribosome 30S subunit by specificity, suppresses the growth of peptide chain and influences the synthetic of bacterioprotein.
Ribavirin: have another name called ribavirin, virazole; Be a kind of strong single phosphoric acid inosine (IMP) dehydrogenase inhibitor, suppress IMP, thereby hinder the synthetic of viral nucleic acid.This product is the broad-spectrum antiviral nucleoside compound, can inhibitory action be arranged to multiple RNA, DNA viruses, as respiratory syncytial virus, influenza virus, herpes simplex virus etc. inhibitory action is arranged.Be mainly used in preventive and therapeutic effect clinically to influenza (causing), adenovirus pneumonia, hepatitis A, herpes, measles etc. by influenza virus A and B.
N-acetylcystein: these product claim acetylcystein as expectorant, easily cough quiet.Heavy-gravity sputum there is decomposition.The mechanism of action is that sulfydryl contained in this product molecular structure can make the disulfide bonds in the sticking apoplexy due to phlegm mucin polypeptide chain, and mucin is decomposed, and has reduced the viscosity of sputum, makes it liquefaction and is easy to expectoration.The thick sputum that is applicable to acute and chronic respiratory tract disease is difficult for expectoration person, and sticking in a large number stagnation of phlegm plug and cause the critical symptom of inhaling because of difficulty.
Epidermal growth factor (EGF) derives from the Mus source: can secrete by gastric acid inhibitory, promote ulcer healing, gastrointestinal tract mucosa is had protective effect, also have the effect that promotes growth of mucosa cell and propagation.
The invention has the beneficial effects as follows: the compound preparation that adopts antibiolics, antiviral agents, expectorant and epidermal growth factor to share has efficient therapeutical effect to the fowl respiratory symptom.By three-dimensional prescription, many infection reasons are all considered carefully not allow a kind of pathogenic microorganism slip through the net; Fatal reason is considered comprehensively antiinflammatory, sterilization, antiviral, inhibition mycoplasma, lifting immunity, reparation mucosa, control secondary infection.The present invention prepares simply, and effect is remarkable, is widely used.
The specific embodiment
Below in conjunction with preferred embodiment, to details are as follows according to the specific embodiment provided by the invention:
Embodiment 1
Take by weighing raw material respectively according to following proportioning: tylosin tartrate 20g, doxycycline hydrochloride 20g, ribavirin 5g, N-acetylcystein 10g, epidermal growth factor 5g, add anhydrous glucose or oral glucose to 100g, mix homogeneously is promptly made a kind of specific compound soluble powder-compound recipe tylosin tartrate soluble powder that is used for the treatment of respiratory disease of birds.Described raw material is the commercially available prod.
Embodiment 2
Take by weighing raw material respectively according to following proportioning: tylosin tartrate 15g, doxycycline hydrochloride 25g, ribavirin 8g, N-acetylcystein 6g, epidermal growth factor 3g, add anhydrous glucose to 100g, mix homogeneously is promptly made a kind of specific compound soluble powder that is used for the treatment of respiratory disease of birds.Described raw material is the commercially available prod.
Embodiment 3
Take by weighing raw material respectively according to following proportioning: tylosin tartrate 10g, doxycycline hydrochloride 15g, ribavirin 10g, N-acetylcystein 15g, epidermal growth factor 4g, add anhydrous glucose to 100g, mix homogeneously is promptly made a kind of specific compound soluble powder that is used for the treatment of respiratory disease of birds.Described raw material is the commercially available prod.
Using method: spraying or drinking-water use, and every bag of 100g converts water 100kg, once a day, and logotype 4 ~ 5 days.
Effect: spray delivery is specially adapted to serious mixed infection, be at death's door, do not eat do not drink, the chicken group of serious airsacculitis, evening spray delivery during 18:00 ~ 20:00, the pathogenic microorganism that infects respiratory system is had killing action completely, can be at the shortest time inner control respiratory symptom; At utmost reduce mortality rate, reduce the loss.Respiratory symptom is alleviated in the death of spray delivery meeting quick control rapidly, reduces chicken group stress, helps treating disease, recovers normal.
The example of treatment fowl upper disease:
Incidence: 3500 of laying hens are raised on a household basis in a certain raising in Tangshan City, Hebei province, and the chicken group phenomenon that occurs generally having loose bowels the first tenday period of a month last Jul, but mental status is also relatively better must treat after 5 days full group's recovery normally with the intestinal bar.The chicken group occurred symptoms of respiratory disease again on 18th in JIUYUE, fail to respond to any medical treatment with crude drug such as erythromycin, virazoles, and every day, dead chicken reached about 20, surplus JIUYUE dead chicken on the 23rd reaches 50.
Clinical symptoms: tangible symptoms of respiratory disease appears in full chicken group, stretches neck and breathes, asthma, get rid of head, the decline of searching for food, spirit is depressed, beak edge sialorrhea has the material slag to stop up on the nostril, a slight swollen phenomenon appears in the part chicken, draw yellowish green, celadon loose stool, walk lamely, asthenia, the liquid of foam sample is arranged in the eyes, aganoblepharon up and down, the phenomenon of one-sided swelling around the eyes appears in the part chicken, and death is arranged individually, and dead chicken whole body is aubergine.Pathological change: analyse altogether and check 8, the following inspection symptom of cuing open is arranged: (1) throat hyperemia, hemorrhage has the muddy mucus of canescence, annulus trachealis hyperemia, hemorrhage, especially seriously ill and dead chicken in the trachea; The air bag muddiness, airbag wall thickens, and has to be " beads shape " yellow or linen scattered cheesy thing, and what have is also shown in linen acid smell thick liquid.The liquid that blister is arranged in the eyes, conjunctival congestion has cheesy exudate.(2) the glandular stomach mucus is canescence: muddiness, and the pancreas hyperemia of part chicken, the edge is lavender, and there is the downright bad point of yellow-white, lark that is dispersed on the surface; The intraperitoneal of part chicken has containing of canescence or lark of foamy liquid, hemorrhage, the swelling of intestinal lymph node folliculus, and the intestinal wall attenuation, partial enteral is Catarrhal or hemorrhagic enteritis.(3) the wherein liver enlargement of a chicken, spleen is little swollen, and kidney has slight congested phenomenon.The tarsal joint enlargement of two chickens is arranged, in the liquid of canescence or white paste is arranged, the conjunctival congestion of part clavus, eyelid is red and swollen also to stick together.
Diagnosis: comprehensive above-mentioned incidence, clinical symptoms and pathological change, but tentative diagnosis is the mixed infection of chicken mild flu with mycoplasma.Prophylactico-therapeutic measures: isolate the morbidity chicken, to its independent raising, the dispensing treatment; Local buried away from chicken house of the corpse of chicken of will dying of illness; Relevant apparatus in the full chicken house, facility etc. are sterilized completely, the chicken group is carried out disinfection of drinking water.Therapeutic scheme and effect: spraying or drinking-water use medicine of the present invention, promptly are used for the treatment of the compound soluble powder of respiratory disease of birds, and every bag of 100g converts water 100kg; Once a day, logotype is 4 ~ 5.This disease be because sudden change, the wind of weather was bigger at that time, raise the family and fail to take prevention and control measure timely, the chicken group is subjected to stress infection morbidity, body constitution is weak, and secondary mycoplasma infection, make sx, mortality rate increases.So, when chicken mass-sending sick, can not be dogmatic and diagnosis dispensing optionally should correctly be diagnosed, the etiological treatment of suiting the medicine to the illness can not mistaken diagnosis and delay treatment causes unnecessary loss.Through treatment in a few days, full group chicken has recovered health, and every of cost of treatment only is 0.25 yuan, raises the family and has obtained very satisfied effect.
The above-mentioned description of the compound soluble powder that is used for the treatment of respiratory disease of birds being carried out with reference to embodiment; be illustrative rather than determinate; can enumerate several embodiment according to institute's limited range; therefore in the variation and the modification that do not break away under the general plotting of the present invention, should belong within protection scope of the present invention.
Claims (3)
1. compound soluble powder that is used for the treatment of respiratory disease of birds, it is characterized in that: by 100g is that Unit Weight is mixed and made into by following component: tylosin tartrate 5-20g, doxycycline hydrochloride 10-30g, ribavirin 5-10g, N-acetylcystein 5-20g, epidermal growth factor 2-5g, surplus is the adjuvant that pharmaceutically is suitable for.
2. the compound soluble powder that is used for the treatment of respiratory disease of birds according to claim 1, it is characterized in that: by 100g is that Unit Weight is mixed and made into by following preferable content component: tylosin tartrate 20g, doxycycline hydrochloride 20g, ribavirin 5g, N-acetylcystein 10g, epidermal growth factor 5g, surplus is the adjuvant that pharmaceutically is suitable for.
3. the compound soluble powder that is used for the treatment of respiratory disease of birds according to claim 1 and 2 is characterized in that: the described adjuvant that pharmaceutically is suitable for is anhydrous glucose or oral glucose.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010131385A CN101780270A (en) | 2010-03-24 | 2010-03-24 | Compound soluble powder for treating respiratory diseases of birds |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010131385A CN101780270A (en) | 2010-03-24 | 2010-03-24 | Compound soluble powder for treating respiratory diseases of birds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101780270A true CN101780270A (en) | 2010-07-21 |
Family
ID=42520494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010131385A Pending CN101780270A (en) | 2010-03-24 | 2010-03-24 | Compound soluble powder for treating respiratory diseases of birds |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101780270A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105535936A (en) * | 2016-01-26 | 2016-05-04 | 苟斌书 | Compound antibacterial preparation for treating pneumonia of foxes, martens and raccoon dogs |
| CN105641548A (en) * | 2016-01-22 | 2016-06-08 | 江西傲新生物科技有限公司 | Medicine composition for preventing, treating and purifying porcine reproductive and respiratory syndrome and preparing method and application thereof |
| CN106902082A (en) * | 2017-03-03 | 2017-06-30 | 安徽安丰堂动物药业有限公司 | A kind of tylosin tartrate soluble powder compound method for birds |
| US20200360405A1 (en) * | 2017-04-19 | 2020-11-19 | The Henry M. Jackson Foundation for the Advancement of Midicine, Inc. | Compositions and methods for reducing local and systemic risks of envenomation |
| CN113940312A (en) * | 2021-11-01 | 2022-01-18 | 北京市华都峪口禽业有限责任公司 | Breeding method for laying hens |
-
2010
- 2010-03-24 CN CN201010131385A patent/CN101780270A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105641548A (en) * | 2016-01-22 | 2016-06-08 | 江西傲新生物科技有限公司 | Medicine composition for preventing, treating and purifying porcine reproductive and respiratory syndrome and preparing method and application thereof |
| CN105535936A (en) * | 2016-01-26 | 2016-05-04 | 苟斌书 | Compound antibacterial preparation for treating pneumonia of foxes, martens and raccoon dogs |
| CN106902082A (en) * | 2017-03-03 | 2017-06-30 | 安徽安丰堂动物药业有限公司 | A kind of tylosin tartrate soluble powder compound method for birds |
| US20200360405A1 (en) * | 2017-04-19 | 2020-11-19 | The Henry M. Jackson Foundation for the Advancement of Midicine, Inc. | Compositions and methods for reducing local and systemic risks of envenomation |
| CN113940312A (en) * | 2021-11-01 | 2022-01-18 | 北京市华都峪口禽业有限责任公司 | Breeding method for laying hens |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101780270A (en) | Compound soluble powder for treating respiratory diseases of birds | |
| CN103977089B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and fosfomycin | |
| ES2873075T3 (en) | Lactobacillus plantarum probiotic strains for urinary tract infections | |
| CN103948691B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and sulfamonomethoxine sodium | |
| RU2678105C2 (en) | Application of taurine for prevention and / or treatment of diseases caused by coronaviruses viruses and / or rotaviruses | |
| US11141382B2 (en) | Sintered nanoparticles and use of the same against a virus | |
| TWI656872B (en) | Antiviral effects of narasin in swine feed | |
| CN104337847B (en) | A kind of livestock and poultry compound medicine containing phoenix-tail fern and phosphonomycin | |
| CN104971124B (en) | A kind of new application of pharmaceutical composition | |
| CN102813910B (en) | Medicine composition used for controlling poultry airsacculitis, and preparation method thereof | |
| CN101530405B (en) | Citric acid and compound citric acid application in pharmacy | |
| CN102813909A (en) | Compound doxycycline hydrochloride composition for preventing and treating colibacillosis and chronic respiratory disease of poultry as well as preparation method thereof | |
| CN108853081B (en) | Application of amentoflavone in preparation of medicine for treating necrotic enteritis of chicken | |
| CN102247399B (en) | Medicament composite and injecta for treating swine streptococcosis | |
| CN101972325A (en) | Medicament composition for treating chick coccidiosis and preparation method thereof | |
| CN102755342B (en) | Compound paracetamol injection and preparation method thereof | |
| CN101780266A (en) | Compound preparation for preventing and treating respiratory disease of livestock and poultry | |
| CN101780064B (en) | New application of p-hydroxyl cinnamic acid | |
| CN102293764B (en) | New application of p-hydroxycinnamic acid | |
| CN102429993B (en) | Compound oral liquid for treating poultry colibacillosis mixed infection | |
| CN116059276B (en) | Pharmaceutical composition for resisting porcine epidemic diarrhea virus and preparation method and application thereof | |
| CN106236758B (en) | Compound preparation for treating chicken respiratory tract bacterial and virus mixed infection and preparation method thereof | |
| Latifi et al. | Coronavirus Disease 2019 “Covid-19” and Its Relation to Food | |
| CN104435995B (en) | Purposes of the tsaoko in preparing treatment and/or preventing the herbal medicine of colibacillosis | |
| CN104586874A (en) | Medicine for preventing and treating respiratory tract infection of birds and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20100721 |